Press Releases April 22, 2026 04:10 PM

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th

OraSure Technologies to Report Q1 2026 Financial Results and Hold Earnings Call on May 6

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
OSUR

OraSure Technologies, Inc. has scheduled its conference call for May 6, 2026, to discuss its first quarter 2026 financial results and business developments. The company is a leader in rapid diagnostic tests and sample collection devices, serving various healthcare sectors globally.

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OSUR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Earnings call scheduled for May 6, 2026, at 5 p.m. ET to discuss Q1 financial results and business updates.
  • OraSure’s products focus on rapid diagnostic tests and sample collection, serving clinical labs, hospitals, research institutions, and more worldwide.
  • The company operates through several subsidiaries including DNA Genotek, Sherlock Biosciences, and BioMedomics.

BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.

A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended.

About OraSure Technologies, Inc. 
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com

Investor Contact: Media Contact:Jason Plagman Amy KochVP, Investor Relations Director, Corporate [email protected] [email protected]



Risks

  • Potential market and regulatory risks impacting diagnostic test demand and development.
  • Uncertainties related to competitive pressures in the healthcare diagnostics sector.
  • Dependence on continued innovation and adoption of decentralized diagnostic solutions by healthcare providers and consumers.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026